MONROVIA, Calif.--(BUSINESS WIRE)-- Prolacta Bioscience, the first and only company to offer human milk fortifier (HMF) made from 100% human breast milk for premature and critically ill infants, has announced that they will donate funds to Susan G. Komen for the Cure® in support of the fight against breast cancer. The synergy between Prolacta and Komen for the Cure is natural, as there is a correlation between breast-feeding and a reduced risk of breast cancer in women.
Prolacta’s financial commitment is to donate one dollar to Komen per ounce of qualified breast milk collected through the Helping Hands Milk Bank (www.helpinghandsbank.com). Their minimum annual commitment will be $25,000, which will help Komen fund life-saving research and community outreach projects. Komen is the world’s largest grassroots network of breast cancer survivors and activists fighting to save lives, empower people, ensure quality care for all and energize science to find the cures.
“We are delighted to be working with Komen,” said Scott Elster, CEO of Prolacta. “We believe that an exemplary way to honor our donor mom’s charitable act is to reciprocate with one of our own. Mothers who selflessly donate to help preterm infants will now also be contributing to the fight against breast cancer.”
Prolacta’s Prolact+ H2MFTM is the first and only commercially available human milk fortifier made from 100% human breast milk. The current standard practice in the NICU uses bovine milk-based products for human milk fortification. A recent study published in the Journal of Pediatrics has demonstrated that for very low-birth-weight preterm infants in the neonatal intensive care unit, a completely human breast milk diet decreases the incidence of necrotizing enterocolitis (NEC) and surgeries related to NEC.
“Susan G. Komen for the Cure’s partnership with Prolacta Bioscience is a unique partnership that will contribute funds for life-saving research and breast health education,” said Katrina McGhee, senior vice president, global business development & partnerships. “Being female and getting older are the two most significant risk factors for breast cancer and this partnership enables women to share our promise to save lives and end breast cancer.”
About Susan G. Komen for the Cure®
Nancy G. Brinker promised her dying sister, Susan G. Komen, she would do everything in her power to end breast cancer forever. In 1982, that promise became Susan G. Komen for the Cure, which is now the world’s largest breast cancer organization and the largest source of nonprofit funds dedicated to the fight against breast cancer with nearly $1.5 billion invested to date. For more information about Susan G. Komen for the Cure, breast health or breast cancer, visit www.komen.org or call 1-877 GO KOMEN.
About Prolacta
Prolacta Bioscience, Inc. (www.prolacta.com) is a life science company dedicated to improving quality of life by Advancing the Science of Human MilkTM. Prolacta creates specialty formulations made exclusively from human milk for the nutritional needs of critically ill premature infants in Neonatal Intensive Care Units. It is the first and only company to provide a human milk fortifier made from 100% human milk, Prolact+ H2MFTM. They operate a pharmaceutical grade processing plant and have designed and patented processes that enable them to make their one-of-a-kind life saving products. Prolacta is committed to making a meaningful difference in the lives of the most vulnerable infants through world-class research and innovative products.
CONTACT:
Prolacta Bioscience
Loren Kosmont, 310-721-9444
[email protected]
KEYWORDS: United States North America California
INDUSTRY KEYWORDS: Health Hospitals Other Health Philanthropy Fund Raising
MEDIA: